| Name | Title | Contact Details |
|---|---|---|
Jessica Sergi |
Associate General Counsel | Profile |
Wendy Sussman |
Vice President, US Healthcare Government and Public Affairs | Profile |
Troy Morgan |
Chief Compliance Officer | Profile |
Michael MacDougall |
Senior Vice President and General Counsel | Profile |
Deborah Logan |
Associate General Counsel | Profile |
Oncobiologics, Inc. has changed its name to Outlook Therapeutics, Inc. Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). ONS-5010 is currently in its first clinical trial, which is being conducted outside of the U.S. and is designed to serve as the first of two adequate and well controlled studies for wet AMD.
Seven Bridges is the industry-leading unified bioinformatics solutions company accelerating precision medicine by enabling the understanding of biomedical data. Our platform, analytic tools, and services expertise are driving discovery and drug development at the world`s leading academic, biotechnology, government, hospitals, and pharmaceutical entities. Through our collaboration with the largest genomics projects, we connect the world`s biomedical information to enable the most efficient analysis at scale.
Response Biomedical Corporation is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California.
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of infectious disease.